Over the years, upregulation of USP22 has been validated in several cancers such as breast, colorectal, pancreatic, lung, ovarian, bladder, lymphoma, glioma, mesothelioma, neuroblastoma, etc. [17,31,49-53]. This evidence concerns the gene USP22 and central nervous system cancer.